ReviewCureus2024
A Comprehensive Review on Solid Lipid Nanoparticles as a Carrier for Oral Absorption of Phyto-Bioactives.
Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Enhancing Oral Bioavailability of Poorly Water-Soluble Natural Products via Lipid-Drug Conjugates.Pharmaceutics · 2026Article
- Nanotechnology in Cancer Therapy: How Nanoparticles Are Shaping the Future of Personalized Treatment.ACS nano medicine · 2026Review
- Bridging bioactive metabolites ofFrontiers in pharmacology · 2026Review
- Advances in Oral Drug Delivery Systems for Natural Polyunsaturated Fatty Acids: Enhancing Bioavailability and Therapeutic Potential.Pharmaceutics · 2025Review
- Enhancing the therapeutical potential of metalloantibiotics using nano-based delivery systems.Beilstein journal of nanotechnology · 2025Review
- Nanoencapsulation of nutraceuticals: enhancing stability and bioavailability in functional foods.Frontiers in nutrition · 2025Review
- Nanoengineered phytochemicals overcome blood-brain barrier constraints in neurodegenerative disorders.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phyto-bioactive (PB) compounds are naturally occurring substances derived from plants that offer significant health benefits ranging from antioxidant and anti-inflammatory activities to potential cancer-fighting properties. However, their widespread application is limited by several inherent limitations, such as low bioavailability, poor biostability, limited aqueous solubility, and no site-specific target. Additionally, the necessity for high concentrations of effective PBs doses further restricts their use. Encapsulating PBs in suitable nanocarriers, particularly solid lipid nanoparticles (SLNs), can enhance their stability in biological environments, improve water solubility, enable controlled release, and allow for targeted delivery. This innovative approach increases bioavailability, reduces toxicity, and potentially lowers effective dosages. The current review examines the critical factors influencing oral PBs delivery, explores how biocompatible and biodegradable SLNs can be optimized to overcome these challenges, and discusses emerging techniques in nanoparticle design that could further enhance the efficacy of PBs delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.